Catherine Bollard, M.D., is the CEO of Cabaletta Bio, Inc., and has a rich background in medicine, particularly in cancer and immunology. She has been shaping the future of cell therapy as the Director of the Center for Cancer and...

Catherine Bollard, M.D., is the CEO of Cabaletta Bio, Inc., and has a rich background in medicine, particularly in cancer and immunology. She has been shaping the future of cell therapy as the Director of the Center for Cancer and Immunology Research at the Children’s National Health System. Dr. Bollard has extensive experience, having served as a Professor at George Washington University and worked with the FDA on cell therapies. She's also been a leader in organizations like the International Society for Cell Therapy. Even though her annual salary is around $480,500, there are no bonuses or stock awards in her compensation package for 2023. Notably, she was involved in the creation of the Science and Technology Committee at Cabaletta, showcasing her commitment to guiding research efforts. Her role is vital in steering the company through challenges, and her medical expertise plays a key part in deciding the future of innovative treatments for patients. She brings a mix of academic prowess and hands-on leadership into her position, influencing both company strategy and scientific advancement.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Cabaletta Bio, Inc. CEOs

C

Catherine Bollard

Ex-CEO of Cabaletta Bio, Inc.

Education

MD from Stanford University

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

March 10, 1973 - 52 years ago

CEO of Cabaletta Bio, Inc. for

2 years 0 months (Jun 2021 - Jul 2023)

Previous Experience

Director of Research at ABC Pharmaceuticals

Rivals

Competitors/colleagues of Catherine Bollard

Holdings

See how much did Catherine Bollard make over time.

As the CEO of Cabaletta Bio, Catherine Bollard has been involved in insider trading activities within the company. Her trades reflect a gradual ramp-up in activity, with the value of her trades increasing consistently over time. She started in 2022...

As the CEO of Cabaletta Bio, Catherine Bollard has been involved in insider trading activities within the company. Her trades reflect a gradual ramp-up in activity, with the value of her trades increasing consistently over time. She started in 2022 with small trades of just a few thousand dollars, like $1.63K in October and gradually moved into larger trades, reaching $19.56K by December 2023. Throughout early 2024, her trading peaked at $23.20K in February before tapering off slightly. This pattern not only highlights her engagement with the company's stock but also reflects a strategic approach to trading as the company progresses. Her holdings and trading activity indicate a strong belief in Cabaletta’s growth potential in biopharma, particularly in further developing therapies that can transform patient care.

Mar 17, 2025

C

shares

CABA @ $1.79

Insider Trading

See recent insider trades of Catherine Bollard.

CABA

$993.50

CABA at $0.99/share

Oct 18, 2022

Purchase

Compensation History

See how much did Catherine Bollard make over time.

In 2023, Catherine Bollard's compensation package totaled $480,500, consisting solely of her base salary, as no bonuses or stock awards were granted during the year. This steady salary suggests a focus on aligning with company goals rather than performance incentives tied to bonuses. In the previous years, her compensation included a bonus of $348K in 2021 based on her contributions to the company's performance, indicating that when performance metrics are met, substantial rewards are available. Her role as a leader shapes how compensation aligns with the company’s success in navigating complex challenges in biotechnology. The consistent salary structure might also reflect a commitment to long-term growth over short-term gains, which is important in such a rapidly evolving sector.

Year

2023

Total Compensation

$480.50K

Salary

$480.50K

Board Justification

The compensation philosophy is to align executive compensation with company performance and market benchmarks.

Bonus

$0.00

Board Justification

No bonus was awarded for the year 2023.

Other

$0.00

Board Justification

No other compensation was reported for 2023.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock awards vested in 2023.

Performance Metrics

Performance metrics for 2023 were based on individual and company performance, with a target bonus rate of 40% of base salary.

Other Cabaletta Bio, Inc. CEOs

Here are other CEOs of Cabaletta Bio, Inc.

Shawn Tomasello

CEO of Cabaletta Bio, Inc.

July 2023 - Present